Lilly's 2,339-person trial ran 18 months with no approval date yet. Lilly warns any retatrutide sold outside its trials is illegal, and two deaths were reported to the FDA.
Recap by typeshit. Full story at Yahoo.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Korea's SBS asks whether Wegovy should be covered by national health insurance as reports of vision loss side effects put the drug under scrutiny.
The eye clinic says most people on GLP-1 medicines don't need extra eye checks, but advises staying alert to any shift in eyesight.
Loading…